Smith & Nephew Yönetim

Yönetim kriter kontrolleri 3/4

Smith & Nephew CEO'su Deepak Nath, Apr2022 tarihinde atandı, in görev süresi 2.58 yıldır. in toplam yıllık tazminatı $ 4.66M olup, şirket hissesi ve opsiyonları dahil olmak üzere 32.5% maaş ve 67.5% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.018% ine doğrudan sahiptir ve bu hisseler € 1.92M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 3 yıl ve 2.8 yıldır.

Anahtar bilgiler

Deepak Nath

İcra Kurulu Başkanı

US$4.7m

Toplam tazminat

CEO maaş yüzdesi	32.5%
CEO görev süresi	2.6yrs
CEO sahipliği	0.02%
Yönetim ortalama görev süresi	3yrs
Yönetim Kurulu ortalama görev süresi	2.8yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Deepak Nath'un ücretlendirmesi Smith & Nephew'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 29 2024	n/a	n/a	US$305m
Mar 29 2024	n/a	n/a	US$284m
Dec 31 2023	US$5m	US$2m	US$263m
Sep 30 2023	n/a	n/a	US$241m
Jul 01 2023	n/a	n/a	US$218m
Apr 01 2023	n/a	n/a	US$221m
Dec 31 2022	US$6m	US$1m	US$223m

Tazminat ve Piyasa: Deepak 'ın toplam tazminatı ($USD 4.66M ) German pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 4.81M ).

Tazminat ve Kazançlar: Deepak 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Deepak Nath (52 yo)

2.6yrs

Görev süresi

US$4,658,252

Tazminat

Dr. Deepak S. Nath, Ph D., serves as Director at Smith & Nephew plc since April 1, 2022. He served as Head of Diagnostics at Siemens Healthineers AG since 2021 until 2022 and served as its President of Lab...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Deepak Nath	CEO & Director	2.6yrs	US$4.66m	0.018% € 1.9m
John Rogers	CFO & Executive Director	less than a year	Veri yok	Veri yok
Paul Connolly	President of Global Operations	3.1yrs	Veri yok	0.0019% € 194.8k
Andrew Swift	Vice President of Investor Relations	no data	Veri yok	Veri yok
Helen Barraclough	Group General Counsel & Company Secretary	2.8yrs	Veri yok	0.0040% € 416.7k
Alison Parkes	Chief Compliance Officer & Compliance APAC	2.8yrs	Veri yok	0.00025% € 26.0k
Joe Metzger	Senior Vice President of Marketing Services & Communications	13.8yrs	Veri yok	Veri yok
Philip Cowdy	Chief Corporate Development & Corporate Affairs Officer	no data	Veri yok	0.0066% € 691.8k
Elga Lohler	Chief Human Resources Officer	8.9yrs	Veri yok	0.019% € 1.9m
Vasant Padmanabhan	President of Research & Development and Ear	8.3yrs	Veri yok	0.014% € 1.5m
Steve Kane	Head of Human Resources for the US	no data	Veri yok	Veri yok
Ian Melling	Senior Vice President of Group Finance	no data	Veri yok	Veri yok

3.0yrs

Ortalama Görev Süresi

55yo

Ortalama Yaş

Deneyimli Yönetim: NPW1 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Deepak Nath	CEO & Director	2.6yrs	US$4.66m	0.018% € 1.9m
John Rogers	CFO & Executive Director	less than a year	Veri yok	Veri yok
Marc Owen	Independent Director	7.1yrs	US$206.78k	0.0020% € 206.3k
Simon Lowth	Independent Non-Executive Director	less than a year	Veri yok	0.000030% € 3.1k
Rupert Soames	Independent Non-Executive Chairman	1.6yrs	US$180.82k	0.0023% € 236.5k
Angela Risley	Senior Independent Director	7.2yrs	US$118.56k	0.00069% € 71.9k
Changzheng Ma	Independent Non-Executive Director	3.8yrs	US$171.78k	0.00024% € 25.0k
Jeremy Maiden	Independent Non-Executive Director	1.2yrs	US$26.24k	0.00015% € 15.6k
Katarzyna Mazur-Hofsaess	Independent Non-Executive Director	4yrs	US$93.06k	0.00021% € 21.9k
Joanna Hallas	Independent Non-Executive Director	2.8yrs	US$93.06k	0.00065% € 67.7k
Robert White	Independent Non-Executive Director	4.5yrs	US$164.78k	0.00093% € 96.9k

2.8yrs

Ortalama Görev Süresi

62yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: NPW1 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilmiyor ( 2.8 yıllık ortalama görev süresi), bu da yeni bir yönetim kurulu olduğunu gösteriyor.

Smith & Nephew Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

Smith+Nephew Announces Board and Committee Changes

Smith & Nephew plc Announces Board Changes

Smith & Nephew plc, Annual General Meeting, May 01, 2024

Smith+Nephew Announces Board Changes

Smith+Nephew Announces Board Changes

Smith & Nephew plc Announces Appointment of John Rogers as CFO

Recent updates

Smith & Nephew plc Provides Earnings Guidance for the Full Year 2024 and for 2025

Investor sentiment deteriorates as stock falls 17%

Smith & Nephew plc to Report Fiscal Year 2024 Results on Feb 25, 2025

Smith+Nephew Announces LEGION Hinged Knee System Now Available in the United States with Proprietary OXINIUM (Oxidized Zirconium)

Smith+Nephew Announces Board and Committee Changes

Upcoming dividend of US$0.14 per share

First half dividend of US$0.14 announced

First half 2024 earnings released: EPS: US$0.24 (vs US$0.20 in 1H 2023)

Smith & Nephew plc Provides Revenue Guidance for the Second Half and Reaffirms Earnings Guidance for the Year 2024

Smith+Nephew Announces 510(K) Clearance of New Catalysystem Primary Hip System

Cevian Capital II GP Limited acquired 5.02% stake in Smith & Nephew plc (LSE:SN.).

Smith & Nephew plc Announces Final Dividend of the Year Ended 31 December 2023, Payable on May 22, 2024

Smith & Nephew plc to Report First Half, 2024 Results on Aug 01, 2024

Smith+Nephew Introduces the RENASYS EDGE Negative Pressure Wound Therapy System

Smith & Nephew plc Announces Board Changes

Upcoming dividend of US$0.23 per share

New minor risk - Earnings quality

Smith & Nephew plc, Annual General Meeting, May 01, 2024

Smith & Nephew plc Recommends Final Dividend for 2023, Payable on May 22, 2024

Final dividend of US$0.23 announced

Smith & Nephew plc Provides Earnings Guidance for 2024

Full year 2023 earnings released: EPS: US$0.30 (vs US$0.26 in FY 2022)

Smith+Nephew Announces Commercial Launch of Its Aetos Shoulder System for Anatomic and Reverse Shoulder Replacement At Aaos 2024 Annual Meeting

Smith & Nephew plc Announces Standout Results for Its Regeneten Bioinductive Implant from A Recently Completed Randomized Controlled Trial

Smith & Nephew plc (LSE:SN.) acquired CartiHeal (2009) Ltd.

Smith+Nephew Announces Board Changes

Smith+Nephew Announces Board Changes

Smith & Nephew plc (LSE:SN.) entered into a definitive agreement to acquire CartiHeal (2009) Ltd. for $330 million.

Smith & Nephew plc Provides Earning Guidance for Full Year 2023

Smith & Nephew plc Announces Appointment of John Rogers as CFO

Smith & Nephew plc Announces Interim Dividend for 2023, Payable 1 November 2023

Upcoming dividend of US$0.14 per share at 3.1% yield

Smith & Nephew plc Announces Board and Committee Changes

Smith & Nephew plc Increases Revenue Guidance for 2023

First half 2023 earnings released: EPS: US$0.20 (vs US$0.20 in 1H 2022)

Smith & Nephew plc Announces Step Down of Anne-Françoise Nesmes as Chief Financial Officer

Smith+Nephew Announces 510(K) Clearance of its AETOS Shoulder System

Now 21% undervalued

Insider recently bought €132k worth of stock

Upcoming dividend of US$0.23 per share at 2.6% yield

Chief Human Resources Officer recently sold €125k worth of stock

Full year 2022 earnings released: EPS: US$0.26 (vs US$0.60 in FY 2021)

Smith & Nephew plc, Annual General Meeting, Apr 26, 2023

High number of new directors

Smith & Nephew plc to Report Fiscal Year 2022 Results on Feb 21, 2023

Smith & Nephew plc Announces Revenue Guidance for 2022

Smith+Nephew Expands Procedural Innovation with Introduction of JOURNEY(TM) II ROX(TM) Total Knee Solution

Smith+Nephew First to Market with Revision Knee Indication on Robotics Platform

Upcoming dividend of US$0.14 per share

Smith+Nephew Launches OR3O ™ Dual Mobility System in Japan for Use in Primary and Revision Hip Arthroplasty

Smith+Nephew Announces New Data Furthering a Number of Published Studies Supporting the Use of Its REGENETEN Bioinductive Implant in Rotator Cuff Repair

Smith & Nephew plc to Report Q2, 2023 Results on Aug 03, 2023

Smith & Nephew plc Announces Executive Changes

Chairman recently bought €70k worth of stock

First half 2022 earnings released

Smith & Nephew plc Provides Revenue Guidance for the Second Half and Full Year of 2022

Smith+Nephew Launches Clinical Support App to Help Reduce Practice Variation in Wound Care

Smith & Nephew plc Announces Executive Changes

Smith & Nephew plc Announces Executive Changes

Smith+Nephew Announces First Total Hip Replacement Cases on its CORI Surgical System Using RI.HIP Modeler and RI.HIP Navigation

High number of new directors

Smith+Nephew Announces New Study Showing GRAFIX™ Membrane Cut the Rate of Diabetic Foot Ulcer Recurrence in Half Compared to Leading Competitors

Upcoming dividend of US$0.23 per share

Independent Non-Executive Director recently bought €71k worth of stock

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Smith & Nephew plc, Annual General Meeting, Apr 13, 2022

Smith & Nephew plc Provides Revenue Guidance for the Second Half and Year of 2022

Smith+Nephew Expands Next-Generation Handheld Robotic-Assisted CORI™ Surgical System into Total Hip Arthroplasty with RI.HIP NAVIGATION

Smith+Nephew Announces New Indications for Use for its PICO 7 and PICO 14 Single Use Negative Pressure Wound Therapy Systems